相关实验视频

Updated: Jun 17, 2025

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

在1型长QT综合征的转基因子中进行KCNQ1抑制替代基因治疗

Sahej Bains¹, Lucilla Giammarino², Saranda Nimani²

¹Departments of Cardiovascular Medicine, Pediatric and Adolescent Medicine, and Molecular Pharmacology & Experimental Therapeutics, Divisions of Heart Rhythm Services and Pediatric Cardiology, Windland Smith Rice Genetic Heart Rhythm Clinic and The Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Guggenheim 501, Rochester, MN 55905, USA.

European heart journal

|August 8, 2024

概括

使用KCNQ1抑制-替代 (SupRep) 的基因治疗有效地纠正了子中的1型长QT综合征 (LQT1). 这种新的方法使心脏电活动正常化,为LQT1患者提供了希望.

科学领域:

心血管遗传学心血管遗传学
基因治疗基因治疗
分子心脏病学分子心脏病学

背景情况:

第1型长QT综合征 (LQT1) 源于KCNQ1基因变异,导致腹腔动作潜能持续时间 (APD) 延长.
现有的LQT1治疗方法旨在控制症状,但需要治疗方法.

研究的目的:

开发和评估一种新的KCNQ1抑制替代 (SupRep) 基因疗法,用于LQT1.1.
评估SupRep基因疗法在子模型中纠正LQT1表型的疗效.

主要方法:

KCNQ1-SupRep基因疗法使用shRNA进行抑制和shRNA-免疫cDNA进行替代,通过腺相关病毒血清型9传递.
在体内输送通过LQT1子的动脉内根注射进行.
使用12导电心电图和贴片电生理学对隔离的室内心肌细胞进行了有效性评估.

主要成果:

在LQT1子中,KCNQ1-SupRep治疗显著缩短了延长QT指数 (QTi),使其接近野生类型 (WT) 的水平.
与对照组相比,被治疗的LQT1子的心肌细胞中,补丁研究显示正常化了动作潜力的持续时间 (APD90).
接受SupRep治疗的子在β-上腺刺激下表现出类似WT的QTi和APD90反应.

结论:

这项研究为基因治疗纠正LQT1.1提供了第一个动物模型概念验证.
在LQT1子中,KCNQ1-SupRep基因疗法在基线和压力下使QTi和APD90正常化.
对LQT1患者进行KCNQ1-SupRep基因治疗的进一步开发是有必要的,特别是探索静脉注射.

关键词:

AAV9AV9 AAV9 AAV9 AAV9 AAV9 AAV9 AAV9 AAV9 AAV9 基因治疗是一种基因疗法.KCNQ1 一个国家.长时间QT综合征转基因的LQT1子

更多相关视频

Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases

Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases

Published on: November 18, 2013

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

相关概念视频

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...

In-vitro Mutagenesis

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.